Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial

PURPOSE: We retrospectively assessed prognostic value of circulating cell-free DNA (cfDNA) using data from the phase III ALEX study in treatment-naïve, advanced ALK+ non–small cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients were randomized to receive twice-daily alectinib 600 mg (n = 152) o...

Descripción completa

Detalles Bibliográficos
Autores principales: Dziadziuszko, Rafal, Peters, Solange, Mok, Tony, Camidge, D. Ross, Gadgeel, Shirish M., Ou, Sai-Hong Ignatius, Konopa, Krzysztof, Noé, Johannes, Nowicka, Malgorzata, Bordogna, Walter, Morcos, Peter N., Smoljanovic, Vlatka, Shaw, Alice T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365376/
https://www.ncbi.nlm.nih.gov/pubmed/35275991
http://dx.doi.org/10.1158/1078-0432.CCR-21-2840

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365376/
https://www.ncbi.nlm.nih.gov/pubmed/35275991
http://dx.doi.org/10.1158/1078-0432.CCR-21-2840

Ejemplares similares